medigraphic.com

2011, Number 1

<< Back Next >>

Vet Mex 2011; 42 (1)

Serum magnesium levels in healthy dogs submitted to the administration of cisplatin with fluid therapy

Calpa OCA, Roberto DC, Teotônio de CJH, Barboza NA

Language: English/Spanish
References: 26
Page: 47-57
PDF size: 127.36 Kb.


ABSTRACT

Cisplatin is an antineoplastic drug that is used to treat carcinomas and osteosarcomas in dogs. However, it can cause kidney damage which in turn leads to the loss of electrolytes. Concentration of magnesium was evaluated in the blood serum of eight dogs that had undergone therapy with cisplatin. The dogs were divided into two groups. Group 1 was supply with cisplatin (70 mg/m², iv) and to prevent nephrotoxcity, saline solution at 0.9% was administered (25 ml/kg/hour, iv in three hours). The animals in Group 2 were not supplied with cisplatin. There was no significant difference (P ‹ 0.05) between the two groups and the results obtained indicated that the protocol used for Group 1 did not cause changes in the serum concentrations of magnesium. Therefore, it can be concluded that the administration of cisplatin does not cause variations if it is combined with the fluid therapy.


REFERENCES

  1. ANTUNES L M, BIANCHI M L. Antioxidantes da dieta como inibidores da nefrotoxicidade induzida pelo antirumoral cisplatina. Rev Nutr 2004; 17: 89-96.

  2. LEE R H, SONG J M, PARK M Y, KANG S K, KIM Y K, JUNG J S. Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem Pharmacol 2001; 62: 1013-1023.

  3. McKNIGHT J A. Principles of chemotherapy. Clin Tech Small Anim Pract 2003; 18: 67-72.

  4. WALLACE B M. Cancer drug pharmacology and clinical experience. In: WALLACE B M, editor. Cancer in dogs and cats. China: Teton NewMedia, 2002: 349-353.

  5. BRADELIN H A, MANSOUR S, AL M. Agents ameliorating or augmenting the nephrotoxicity of cisplatin. Food Chem Toxicol 2006; 44:1173-1183.

  6. DAGLI M L Z. Agentes Antineoplásicos. Em: SPINOSA H, GÓRNIAK S M, BERNARDI M M, editores. Farmacología aplicada à medicina veterinária. 3ra ed. Rio de Janeiro: Guanabara Koogan, 2002: 581-595.

  7. ANDRADE S F. Terapêutica antineoplásica. Em: ANDRADE S F. Manual de terapêutica veterinária. São Paulo: ROCA, 2002: 179-198.

  8. OGILVIE G K. Chemotherapy. In: OGILVIE G K, editor. Managing the veterinary cancer patient. New Jersey: Veterinary Learning Systems, 1995: 79-81.

  9. RODASKI S, DE NARDI A B. Classificação dos quimioterápicos. Em: RODASKI S, DE NARDI A B, editores. Quimioterapia antineoplásica em cães e gatos. Curitiba: Bio Editora, 2006: 69-73.

  10. LANORE D, DELPRAT C. Principais drogas. Em: LANORE D, DELPRAT C, editores. Quimioterapia anticancerígena. São Paulo: ROCA, 2004: 105-113.

  11. OGILVIE G K. Chemotherapy and the surgery patient: Principles and recent advances. Clin Tech Small Anim Pract 1998; 13: 22-32.

  12. LAJER H, KRISTENSEN M, HANSEN H H, NIELSEN S, FROKIAER J, OSTERGAARD L F et al. Magnesium depletion enhances cisplatin – induced nephrotoxicity. Cancer Chemother Pharmacol 2005; 56: 535-542.

  13. MARTINS M R, DALECK C R, CARVALHO M B, CALADO E B, ZILIOTTO L, DA SILVA F M M. Avaliação dos efeitos de dois protocolos para administração de cisplatina sobre a função renal de cães. Ata Cirúrgica Bras 2003; 18: 314-319.

  14. BADARY O A, ABDEL – MAKSOUD S, AHMED W A, OWIEDA G H. Naringenin Attenuates cisplatin nephrotoxicity in rats. Life Sci 2005; 76: 2125-2135.

  15. CHEW D J, BATEMAN S W. Fluidoterapia para Cães e Gatos. Em: BIRCHARD S J, SHERDING R G, editores. Clinica de pequenos animais. São Paulo: Roca, 2003: 70-80.

  16. NELSON R W, COUTO C G. Princípios de tratamento do câncer. Em: NELSON R W, COUTO C G, editores. Medicina interna de pequenos animais. Rio de Janeiro: Guanabara - Koogan, 2001: 864-866.

  17. WEISS-GUILLET E M, TAKALA J, JAKOB S M. Diagnosis and management of electrolyte emergencies. Best Pract Res Clin Endocrinol Metab 2003; 17: 623-651.

  18. RAFFE M R. Fluidoterapia e terapia por eletrólitos e meios ácido – básicos no paciente cirúrgico. Em: SLATTER D, editor. Manual de cirurgia de pequenos animais. São Paulo: Editora Manole, 1998: 13-35.

  19. HODGKINSON E, NEVILLE-WEBBEY H L, COLEMANY R E. Magnesium depletion in patients receiving Cisplatinbased chemotherapy. Clin Oncol 2006; 18: 710-718.

  20. AL – TWEIGERI T, MAGLIOCCO A M, DECOTEAU J F. Cortical Blindness as a Manifestation of Hypomagnesemia Secondary. Gynecol Oncol 1999; 72: 120-122.

  21. LAJER H, DAUGAARD G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25: 47-58.

  22. WOLF F I, MAIER J A M, NASULEWIEZ A, FEILLETCOUDRAY C, SIMONACCI M, MAZUR A et al. Magnesium and neoplasia: from carcinogenesis to tumor growth and progression or treatment. Arch Biochem Biophys 2006; 458: 24-32.

  23. BEIGUELMAN B A. Análise de variância. Em: BEIGUELMAN B A, editor. Curso pratico de Bioestatística. Ribeirão Preto: FUNPEC – Editora, 2002: 189-219.

  24. MORROW G R, HICKOK J T, ROSENTHAL S N. Progress in reducing nausea and emesis. Cancer 1995; 76: 343-357.

  25. O’KEEFE D A, HARRIS C L. Toxicology of oncologic drugs. Vet Clin North Am Small Anim Pract 1990; 20: 483-504.

  26. HARDIE E M, PAGE R L, WILLIAMS P L, FISCHER W D. Effect of time of cisplatin administration on its toxicity and pharmacokinetics in dogs. Am J Vet Res 1991; 52: 1821-1825.




2020     |     www.medigraphic.com